Facebook
X
LinkedIn
Forward
The 3rd Annual HMNCC GI Oncology Summit - December 4, 2026
In-Person and Virtual attendance options are available.
Presented by the Houston Methodist Dr. Mary and Ron Neal Cancer Center
This Summit will delve into the latest developments in managing gastrointestinal cancers. It will feature expert presentations on advancements in immunotherapy, molecular diagnostics, targeted therapies and new surgical techniques, . Participants will also explore key trends in transplant oncology and the role of precision medicine. Each session will offer insights into disease pathogenesis, risk factors, prevention strategies, and innovative treatments, including discussions on minimally invasive procedures, enhanced imaging, and blood-based biomarkers. The symposium will emphasize how these advancements improve patient outcomes and provide a comprehensive review of current and emerging management strategies for various gastrointestinal cancers.
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Houston Methodist Employees | Complimentary |
| Physician (Private physician located within the Greater Houston Area)* | $175 |
| Physician (Private physician located outside the Greater Houston Area) | Complimentary |
| Research Scientist | Complimentary |
| Allied Health Care Professional / All Others | Complimentary |
| Resident / Fellow / Student | Complimentary |
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.
Presenters, topics, program schedule, and credit is subject to change
Target Audience
This Summit is designed for physician scientists, practicing oncologists, hepatologists, transplant surgeons, physician assistants, advanced nurse practitioners, oncology nurses, gastroenterologists, residents, fellows, medical students, allied health care professionals, and clinical research associates. Attendees involved in hepatobiliary, pancreatic, neuroendocrine, colorectal, esophageal, and gastric cancer care will find valuable insights for advancing their practice and improving patient care.
Learning Objectives
At the conclusion of this activity, the learner should be able to:
- Describe the epidemiology, risk factors, and prevention strategies for gastrointestinal cancers.
- Review the pathogenesis, surveillance modalities, and underuse of screening for hepatocellular carcinoma (HCC), focusing on blood-based biomarkers and management of pre-liver cancer diseases.
- Evaluate transplant-bridging approaches and the role of immunotherapy in both resectable and advanced hepatocellular carcinoma, as well as new developments in treating advanced cholangiocarcinoma.
- Assess updates on operative strategies for early-stage hepatobiliary cancers and transplant oncology for hilar and intrahepatic cholangiocarcinoma.
- Explain the latest advancements in molecular diagnostics, operative and perioperative approaches, and targeted therapies for pancreatic adenocarcinoma, low-/intermediate-grade neuroendocrine carcinoma, and colorectal cancers.
- Discuss advancements in multidisciplinary approaches for managing esophageal and gastric cancers, as well as the role of precision medicine in unresectable gastrointestinal malignancies
Course summary
- 5.00 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.00 Attendance
H O U S T O N M E T H O D I S T N E A L C A N C E R C E N T E R | |
The 3rd Annual GI Oncology Summit | |
TIME | PRESENTATION |
7:00 AM | Registration & Breakfast |
7:50 AM | BREAKFAST PRODUCT THEATRE - |
8:20 AM | Welcome and Leadership Landmark Opening |
8:30 AM | Session 1A: Hepatobiliary Cancer |
8:40 AM | Global Liver Cancer Trends in 2026: |
8:50 AM | AI-Powered for Liver Diseases |
9:00 AM | Transforming Pre-Liver Cancer Management: Hepatologist-Led Precision Therapies |
9:10 AM | Next-Generation Liver Cancers Screening: |
9:20 AM | Precision Management of Cirrhosis-Associated HCC: |
9:30 AM | Panel Discussion |
9:45 AM | Coffee Break |
9:55 AM | Session 1B: Hepatobiliary Cancer |
10:00 AM | Immunotherapy 2.0: Novel Combinations and Biomarkers for HCC in 2026 |
10:10 AM | Precision Medicine in Cholangiocarcinoma: |
10:20 AM | Robotic and Image-Guided Surgery for Early-Stage Hepatobiliary Cancers |
10:30 AM | Transplant Oncology for Cholangiocarcinoma: Genomic-Guided Strategies for 2026 |
10:40 AM | International Perspectives in Hepatobiliary Malignancies |
10:50 AM | Panel Discussion |
11:00 AM | Coffee Break |
11:10 AM | Keynote Address: |
11:30 AM | Session 2: Pancreatic Cancer |
11:35 AM | Targeted Therapies for Pancreatic Cancer: Biomarker-Driven Advances for 2026 |
11:45 AM | AI-Enabled Early Detection and Risk Stratification for Pancreatic Cancer |
11:55 AM | Panel Discussion |
12:05 PM | Patient Perspective |
12:25 PM | Session 3: Colorectal Cancer |
12:30 PM | Precision Radiation Oncology for Colorectal Cancer: Adaptive Therapies in 2026 |
12:40 PM | Advanced Minimally Invasive Surgery for Colorectal Cancer: 2026 Innovations |
12:50 PM | Immunotherapy Landscape in Colorectal Cancer: What’s New and What’s Next? |
1:00 PM | Genomic-Driven Precision Oncology in Colorectal Cancer: |
1:10 PM | Appendiceal Adenocarcinoma: |
1:20 PM | Panel Discussion |
1:35 PM | LUNCH PRODUCT THEATRE - |
2:05 PM | Break |
2:15 PM | LUNCH PRODUCT THEATRE - |
2:45 PM | Session 4: Esophageal and Gastric Cancer |
2:55 PM | Multidisciplinary Advances in Resectable Gastroesophageal Cancers: |
3:05 PM | Immunotherapy and Biomarker Innovations for Unresectable Gastroesophageal Adenocarcinoma |
3:15 PM | Precision Medicine in Gastroesophageal Adenocarcinoma: |
3:25 PM | Panel Discussion |
3:35 PM | Concluding Remarks |
3:45 PM | Adjourn |
LIVE (in-person attendance) will be held in the Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030.
Virtual information will be provided to registered learners at a later date.
Available Credit
- 5.00 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.00 Attendance
Price
FEES
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee. |
|---|